Today's noteworthy upgrades include: Allstate (ALL) upgraded to Outperform from Market Perform at Keefe Bruyette... Anglo Platinum (AGPPY) upgraded to Neutral from Underperform at Credit Suisse... Apple (AAPL) upgraded to Buy from Hold at Societe Generale... AutoNation (AN) upgraded to Overweight from Underweight at Morgan Stanley... Celadon Group (CGI) upgraded to Strong Buy from Market Perform at Raymond James... Centene (CNC) upgraded to Outperform from Market Perform at FBR Capital... Deutsche Boerse (DBOEY) upgraded to Buy from Neutral at Goldman... ESCO Technologies (ESE) upgraded to Buy from Hold at BB&T... Edwards Lifesciences (EW) upgraded to Outperform from Market Perform at Northland... Fortress (FIG) upgraded to Outperform from Market Perform at Keefe Bruyette... Groupon (GRPN) upgraded to Outperform from Neutral at Macquarie... IMAX (IMAX) upgraded to Overweight from Neutral at Piper Jaffray... Ingersoll-Rand (IR) upgraded on nonresidential construction outlook at Stifel... Patterson-UTI (PTEN) upgraded to Buy from Hold at Wunderlich... Pioneer Natural (PXD) upgraded to Overweight from Equal Weight at Morgan Stanley... Ralph Lauren (RL) upgraded to Overweight from Equal Weight at Stephens... Sasol (SSL) upgraded to Buy from Neutral at BofA/Merrill... Skyworks (SWKS) upgraded to Overweight from Equal Weight at Stephens... VOXX (VOXX) upgraded to Buy from Neutral at B. Riley.

Apple (AAPL) supplier TSMC (TSM) has unveiled its A16 chip manufacturing technology featuring nanosheet transistors with "backside power rails" meant for producing its ultra-advanced 1.6nm chips by 2026, Nikkei Asia's Cheng Ting-Fang reports. TSMC says the introduction of the technology can "greatly improve logic density and performance." Reference Link

Sees Q2 revenue $1.62B-$1.7B, consensus $1.64B.

Reports Q1 revenue $1.6B, consensus $1.57B. "Edwards is positioned to extend our leadership and deliver sustainable growth as a result of the strategic investments we have made across our transcatheter platforms to address the large and growing needs of patients impacted by aortic, mitral and tricuspid disease. We are pleased with our total company performance with first quarter sales growth of 10% as more patients were treated with our innovative therapies," said Bernard Zovighian, CEO. "This encouraging start to the year supports our increased 2024 sales guidance. Looking beyond 2024, we remain confident in Edwards' innovation-driven strategy, led by new indications, differentiated technologies and strategic adjacencies for addressing the significant unmet needs of structural heart disease patients."

Pre-earnings options volume in Edwards Lifesciences is 5.5x normal with puts leading calls 10:7. Implied volatility suggests the market is anticipating a move near 4.8%, or $4.27, after results are released. Median move over the past eight quarters is 6.3%.

Alphabet (GOOGL), the parent company of Google, is scheduled to report first quarter 2024 results after the market close on Thursday, April 25, with a conference call scheduled for 4:30 pm Eastern Time. What to watch... To see the rest of the story go to thefly.com. See Story Here

Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus $2.20... Chevron (CVX), consensus $2.87... AbbVie (ABBV), consensus $2.23... HCA Healthcare (HCA), consensus $5.01... Colgate-Palmolive (CL), consensus 81c... Charter (CHTR), consensus $7.92... AutoNation (AN), consensus $4.27.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

JPMorgan lowered the firm's price target on Deutsche Boerse to EUR 193 from EUR 198 and keeps a Neutral rating on the shares.

Apple saw sales of its iPhones fall 19.1% in the first three months of the year, CNBC's Ryan Browne reports, citing data from Counterpoint Research. Meanwhile, Huawei saw a 69.7% surge in smartphone sales in the country during the same period, Counterpoint said. Reference Link

Berenberg initiated coverage of Deutsche Boerse with a Hold rating and $20 price target. While the company's 2024 appears, Berenberg is mindful of longer-term cyclical headwinds to Deutsche Borse's volume-related businesses, including from a moderation of volatility and interest rates, the analyst tells investors in a research note. The firm retains a preference for London Stock Exchange Group, which it thinks provides superior structural growth and revenue stability. It finds Deutsche Boerse fairly valued at current levels.